To view files, you need Adobe Acrobat Reader.
Support and communication for thyroid cancer survivors and families. A free publication of:
Cancer Survivors' Association, Inc.
In This Issue
In 2008, for the sixth year in a row, ThyCa: Thyroid Cancer Survivors' Association, Inc. will award new grants for thyroid cancer research, ThyCa Executive Director Gary Bloom has announced.
Each grant will be for 2 years. One grant will support research on follicular-cell-derived thyroid cancer, including papillary, follicular, anaplastic, and variants. The other grant will support research on medullary thyroid cancer.
The ThyCa Research grants are open to all researchers and institutions worldwide. An independent expert panel of the American Thyroid Association (ATA) will select the grant recipients. ATA is the professional association of clinicians and researchers concerned with thyroid diseases.
The Call for Proposals and eligibility requirements are available on the ATA web site on this page: http://thyroid.org/professionals/education/grants_thyca.html. The deadline for submission of a proposal summary to the ATA is January 31, 2008. The ATA Research Committee will rank proposals according to their scientific merit. ATA will notify the authors of selected proposals by early March and will invite them to submit complete grant applications.
“Research offers hope for finding cures for all types of thyroid cancer, and more thyroid cancer research is urgently needed. We greatly appreciate the ATA’s support in our research grant process,” said ThyCa Executive Director Gary Bloom. "We are grateful to all our generous donors and volunteers for making these grants possible."
The ThyCa grants, begun in 2003, are the first-ever thyroid cancer research grants to be funded entirely by thyroid cancer patients, caregivers, and friends.
ThyCa invites everyone to join us in our quest to find a cure for all thyroid cancer: http://www.thyca.org/donations.htm.
Support Group. Welcome to our new support group in Indianapolis, Indiana.
And thank you to Michelle Irwin for starting the group. The group
meets on the fourth Wednesday of every month. The first meeting will
be the evening of March 26. For details, visit
Group Sets 2008 Meeting Schedule. Welcome to the facilitators Jo Marie
Bushell and Carol Condit of the Denver, Colorado, Support Group, now
meeting on the third Monday evening each month. Find out more at
Group To Hear Guest Speaker at February 9th Meeting. "How Physical
Therapy Can Facilitate Your Recovery" will be the topic at the
February meeting of the Baltimore, Maryland, Support Group. Speaker
will be Cheryl Ambroza, physical therapist at St. Joseph's Hospital
in Baltimore. For meeting details and contact information for Vanda
White, the group’s facilitator, see
Dozens of Groups Meet Each Month. Support group meetings are wonderful ways to meet others in your area, discuss thyroid cancer face to face, and hear and share your experiences and coping tips. Each group has its own web page. Find the group nearest you: www.thyca.org/sg/local.htm.
Want To Start a Group in Your Area? ThyCa will help you. E-mail Sara Brenner, ThyCa’s Director of Support Group Development: at firstname.lastname@example.org.
Thyroid Cancer—New ThyCa E-mail Support Group.
Mark the Dates and Plan to Attend!
Visit our web for details: www.thyca.org/conferences.htm.
in a Clinical Trial: A Patient’s Perspective
Some Questions To Ask Before Entering a Clinical Trial
Possible Risks and Benefits
Participation and Care
Trials: Thoughts from a Patient and Caregiver
There are several types of clinical trials:Prevention trials, Screening trials, Diagnostic trials, Treatment trials, Supportive Care or Quality of Life, Genetic Studies.
Once enrolled, you will be given a signed & dated copy of the consent form for your records. Consent forms will vary depending upon several factors, including disease site & disease stage, intervention proposed and individual Institutional Review Boards (IRB).
ThyCa shares news of new clinical trials for the rare types of thyroid cancers (medullary and anaplastic), and also links to complete lists of all thyroid cancer clinical trials, plus background information for patients, on our web site’s Clinical Trials section (www.thyca.org/clinical_trials.htm).
XL184-001, a study of XL184 in adults with advanced malignancies is currently active and is recruiting participants.
The purpose of this study is to determine the best and safest dose of XL184 administered orally. XL184 is a new chemical entity that inhibits VEGFR2, MET, and RET, kinases implicated in tumor formation, growth, and migration.
At least 20 patients with Medullary Thyroid Cancer (MTC) will be enrolled at the maximum tolerated dose to evaluate the effect of XL184 in this population.
Contacts and Locations
This trial, XL184-001, is active at the following locations:-
Activation is planned at the following locations:
For additional information, please refer to ClinicalTrials.gov.
Current clinical trials open to thyroid cancer patients:
Background information for patients and caregivers, information about some trials for rare thyroid cancer, plus links to all the thyroid cancer clinical trials in the databases of the National Cancer Institute and the American Thyroid Association:
2 cups unbleached
Contributed by Frances P. of Maryland
Thank you, Frances! Your recipe will be added to the next edition of the FREE Downloadable Low-Iodine Cookbook. Download the cookbook, with more than 250 favorite recipes from more than 200 generous volunteers, here: www.thyca.org/Cookbook.pdf.
Invitation! Send your favorite recipe to email@example.com, for a future newsletter and the cookbook’s next edition.
Here are four ways:
ThyCa NEWS NOTES
Thank you to the writers, editors, and proofreaders for this issue: Gary Bloom, Patti Malloy, Frances P., Clayton Twigg, Rose Twigg, and Cherry Wunderlich.
The deadline for articles and news items is the first day of each month. Suggestions for articles are welcome.
We invite you to send News Notes to your family and friends. News Notes are also published on on this page: www.thyca.org/newsletters.htm. For permission to reprint in another electronic or print publication, please contact us.
ThyCa: Thyroid Cancer Survivors' Association, Inc. is a national non-profit 501(c)(3) organization (tax ID #52-2169434) of thyroid cancer survivors, family members, and health care professionals. We are dedicated to support, education, and communication for thyroid cancer survivors, their families and friends, as well as to public awareness for early detection, treatment, and lifetime health monitoring, and to thyroid cancer research fundraising and research grants.
Contact us for free awareness materials and information about our free services and special events. E-mail firstname.lastname@example.org, call 1-877-588-7904, fax 1-630-604-6078, write PO Box 1102, Olney, MD 20830-1102, or visit www.thyca.org.